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Editorial
Targeting metabolic pathways to treat cardiovascular diseases
Cardiovascular disease remains a leading cause of morbidity and
mortality, and according to the World Health Organization represents
an estimated 31% of all deaths worldwide. In the last two decades there
is growing recognition of the importance of metabolism in the cardio-
vascular system as it was found that disturbances in cardiac metabolism
often are at the basis of causing cardiac disease. As a biological pump,
the heart's energy needs are enormous, being responsible for approxi-
mately 10% of whole-body fuel consumption [1]. However, apart from
the critical role of energy metabolism, alterations in various metabolic
pathways directly or indirectly impact on cardiac contractile function.
These include post-translational protein modification, such as palmi-
toylation and O-GlcNAcylation, and metabolism-derived signals such as
bioactive lipids. In line with the emergence of a pivotal role for energy
metabolism, an increasing number of reports have indicated that in-
terventions targeting metabolic pathways, referred to as ‘metabolic
modulation’, are an effective approach to combat cardiovascular dis-
ease, in particular the most prevalent diseases of our time, i.e., diabetes,
heart failure, and the metabolic syndrome. Therefore, novel strategies
and compounds directed at intermediary metabolism are being devel-
oped and already show high promise in the treatment of diabetes and
heart failure. However, these strategies and/or compounds present
numerous challenges concerning their actual mechanism and potential,
requiring in-depth unraveling of their metabolic actions by the research
community.
In order to foster interaction and collaboration among researchers in
this specific field and provide an interactive learning environment for
trainees, in 2001 the Society for Heart and Vascular Metabolism (SHVM)
was founded at the initiative of William C. Stanley (who passed away
untimely in 2013) [2]. Since 2003 the SHVM has held annual meetings
which have become a “must” for any researcher working in the field of
cardiac metabolism. Within the main topic of heart and vascular me-
tabolism, each meeting is focused on a specific theme. These meetings
have facilitated the establishment of many links and fruitful colla-
borations, which have led to a marked advance in our understanding of
the role of cardiac energy metabolism in health and disease.
In 2015 it was decided that the results of the annual SHVM con-
ferences should be made available to a wider audience. The editors of
Biochimica et Biophysica Acta agreed to publish the proceedings of the
13th SHVM meeting, held in Tarrytown (New York, USA), in a Special
Issue of BBA – Molecular Basis of Disease (BBA-DIS). In subsequent
years the publishing of these proceedings in BBA-DIS has become a
tradition. Table 1 lists the SHVM meetings held in 2015–2019 together
with the bibliographic data of its proceedings. Thus, the 17th SHVM
conference was held in Amsterdam, the Netherlands, on June 23–26,
2019, and focused on Targeting metabolic pathways to treat cardiovascular
diseases (www.heartmetabolism.org/2019). As a result, the 5th Special
Issue of BBA-DIS that is devoted to SHVM conference proceedings
consists of 12 contributions from experts in the metabolic field who
each review the state-of-the-art knowledge on a specific aspect of car-
diac and vascular metabolism, thereby especially pinpointing promising
areas for further research. Together, these review articles bring an
overall picture of a further upheaval in metabolic-driven research and
in therapeutic opportunities in our common battle against the most
prevalent cardiovascular diseases.
The annual SHVM meeting started with a trainee workshop on
human induced pluripotent stem (hiPS) cell-derived cardiomyocytes as
a model system for research. Having been one of the pioneers in this
specific field, Robert Passier presented an overview of the current status
of the generation and application of hiPSC-cardiomyocytes [3]. While
in recent years hiPSC-cardiomyocytes are more commonly being ap-
plied in research, they suffer from an immature phenotype which in
many aspects resembles more that of the fetal heart than of the adult
heart. Mechanical and electrical triggers for hiPSC cardiomyocyte ma-
turation have been explored extensively, but only recently focus has
shifted to improve maturation through metabolic parameters. In his
contribution, metabolic changes occurring during human embryonic/
postnatal development and maturation in vivo are taken as a blueprint
for hiPSC-cardiomyocyte maturation in vitro. This approach includes,
for instance, the addition of fatty acids to the culture medium so as to
enhance maturation.
Subsequently, Paul Wijnker demonstrated how engineered heart
tissue can be applied successfully to delineate specific pathology and
treatment responses in patients with hypertrophic cardiomyopathy
(HCM) [4]. HCM is the most common inherited cardiomyopathy but,
with over 1500 associated mutations, many of which cause specific
cellular perturbations. As a result, depending on the mutation, in-
dividual patients will need tailored treatment. Working with en-
gineered heart tissue allows the evaluation of effective treatment op-
tions.
Targeting cardiac fatty acid metabolism is regarded as a primary
approach for metabolic modulation therapy because of the importance
of long-chain fatty acids as the main fuel for myocardial energy pro-
vision which requires a properly controlled rate of fatty acid utilization,
avoiding both too low uptake rates, which could elicit an energy deficit,
and too high uptake rates, which pose the risk of excess lipid accu-
mulation and lipotoxicity. The latter is a main cause of cardiac insulin
resistance and diabetic cardiomyopathy. In their contribution, Sander
Houten and colleagues discuss the essential role of carnitine and car-
nitine acyl-transferases in not only mitochondrial fatty acid β-oxidation
but also peroxisomal β-oxidation [5]. Specifically, the review discusses
the physiological function of exchange of acylcarnitines between per-
oxisomes and mitochondria, an underexplored aspect that may serve a
significant function in the proper handling by the heart of exogenous
long-chain and medium-chain fatty acid species.
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The transmembrane glycoprotein CD36 (SR-B2) is the main myo-
cardial fatty acid transporter and serves a pivotal role in the regulation
of cellular fatty acid uptake. The rate of fatty acid uptake is dependent
on the presence of CD36 in the sarcolemma, which is regulated by
subcellular vesicular recycling of CD36 between endosomes and the
sarcolemma. This mechanism has many similarities with the me-
chanism by which myocardial glucose uptake is regulated by the sub-
cellular recycling of glucose transporter GLUT4. Together, CD36 and
GLUT4 determine the substrate preference of the heart, i.e., the fatty
acid–glucose fuel balance. Recent studies by Joost Luiken et al. [6] have
disclosed trafficking proteins that are distinctly involved in CD36 and
GLUT4 vesicular trafficking. These trafficking proteins, in particular
vacuolar-type H+-ATPase and specific vesicle-associated membrane
proteins (VAMPs), offer promising targets to rectify aberrant substrate
uptake rates and restore a proper fatty acid–glucose fuel balance.
Following the exciting observation that treating diabetic patients
with sodium-glucose co-transporter-2 (SGLT2) inhibitors (collectively
known as gliflozins) has a marked beneficial effect on cardiovascular
disease, reducing mortality and hospitalization for heart failure, the
underlying mechanism has been hotly debated. Several studies have
now revealed that part of the underlying beneficial mechanisms of the
SGLT2 inhibitors can be ascribed to metabolism and ion homeostasis of
the heart, not only providing a direction for therapy for diabetic and
heart failure patients, but also implicating cardiac metabolism and ionic
homeostasis as crucial underlying causal mechanisms of action of these
most prominent novel diabetic (and presumably heart failure) medi-
cines.
Julian Mustroph et al. [7] address the possible role of Ca2+/cal-
modulin-dependent kinase II (CaMKII) and of GLUT1 in the cardiac
beneficial effects of SGLT2i's. CaMKII is often upregulated and hyper-
active in heart failure patients, and its hyperactivity is believed to
contribute to the development of heart failure. In addition, the failing
heart is believed to have a shortage of oxidizable substrates. Several
studies have suggested that SGLT2i's can alter and improve cardiac
metabolism. Recent work by his research group has delineated that
empagliflozin, one of the most promising SGLT2i's for cardiac diseases,
can directly attenuate CaMKII activity and increase GLUT1-associated
glucose uptake into cardiomyocytes. The review discusses these find-
ings and puts them in a broader perspective of the workings of SGLT2i's
in relation to heart failure.
CaMKII and cardiac metabolism as possible cardiac beneficial me-
chanisms of empagliflozin were further evaluated in an experimental
study by Michael Lehrke et al. [8]. They employed an animal model of
type 2 diabetes (db/db mice on a high fat diet) treated with empagli-
flozin for 4½ weeks, and examined cardiac function and plasma me-
tabolic substrate concentrations. The major findings of the study sup-
ported the cardiac beneficial effects of SGLT2 inhibitors: treatment with
empagliflozin improved cardiac diastolic function, reduced mortality,
improved glucose metabolism but was without effects in cardiac ketone
and branched-chain amino acid metabolism.
The severity of post-myocardial infarction (MI) heart failure is to a
large extent determined by the size of the initial infarct during the
evolving MI and its clinical reperfusion treatment. Infarct size is not
only a result of injury occurring during ischemia, but also during the
initial period of reperfusion (so-called “reperfusion injury”), thereby
offering therapeutic potential for interventions during reperfusion in
order to reduce infarct size and, consequently, the degree of heart
failure. Although SGLT2i's do not significantly affect the incidence of
MI, recent pre-clinical studies show that these compounds may reduce
reperfusion injury, infarct size and thus heart failure. This exciting
novel hypothesis about the working of the SGLT2i's is further explored
and discussed in the review by Ionanna Andreadou and co-authors [9],
who concludes that the mitigation of reperfusion injury by SGLT2i's
may be explained by its direct modulation of Na+, Ca2+, the sodium/
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Epidemiological studies have clearly indicated that sex and gender
affect the occurrence, development and consequences of cardiovascular
diseases. For instance, the prevalence of cardiovascular disease is lower
in non-menopausal women than in men of the same age, but it increases
with age and in post-menopausal women becomes the major cause of
mortality. Importantly, gender differences include biological but also
socio-cultural parameters. The putatively complex molecular mechan-
isms underlying sex and gender differences in cardiac pathophysiology
are still poorly understood. Renée Ventura-Clapier and co-workers re-
view current knowledge on gender related differences in energy me-
tabolism [10] to conclude that there is a lack of experimental and
clinical studies addressing this issue. Furthermore, she argues that with
experimental studies more care should be taken to consider and discuss
gender issues and, at least, properly describe the gender studied (details
that are lacking in many published experimental animal studies). Ob-
viously, understanding gender issues is a prerequisite for developing
personalized therapeutic strategies.
Loss of insulin action or function during obesity and diabetes is
known to disrupt energy metabolism in the heart by triggering hy-
perglycemia and fatty acid over-utilization, leading to glucolipotoxi-
city. Thomas Pulinilkunnil and his team at Dalhousie University [11]
have previously demonstrated that glucolipotoxicity negatively reg-
ulates the lysosomal protein degradation pathway or autophagy by
inhibiting transcription factor EB (TFEB), a master regulator of lyso-
somal biogenesis and lysosomal function. In the current paper, they
examine nutrient specific and upstream regulators of TFEB in the heart,
as well as metabolic alterations in response to the loss of TFEB action,
and explore whether these alterations impact on cardiomyocyte func-
tion. By utilizing in vitro, ex vivo and in vivo models of lipid overload,
they demonstrate that saturated fatty acids (such as palmitate), in
contrast to polyunsaturated fatty acids, decreases TFEB content in a
concentration dependent manner. Thus, hearts from mice on high-fat/
high-sucrose diet exhibited a decline in nuclear TFEB content, whereas
adenoviral expression of constitutively active TFEB rescued glucolipo-
toxicity-induced lysosomal dysfunction and cell death. Together, their
data indicate that loss of TFEB is sufficient to remodel substrate me-
tabolism and to render the cardiomyocyte prematurely susceptible to
nutrient overload-induced cell death.
Besides fatty acids and glucose, the heart may also use other sub-
strates for energy provision, such as lactate, ketone bodies and amino
acids [1]. In the last decade ketone bodies have emerged in particular
focus because of several reports indicating their beneficial action on the
failing heart. Ketone bodies serve in carbohydrate-depleted conditions
as glucose-sparing energy substrates, but also have important signaling
functions. Kieran Clarke and her group [12] has applied manipulation
of ketone body metabolism to treat cardiac disease, especially by ad-
ministering exogenous ketone esters, and in their review discuss the
state-of-the-art on both our molecular understanding of the beneficial
role of ketones for heart disease and practical aspects of its therapeutic
application.
Structural and functional alterations in mitochondria have long
been known to play a key role in the pathogenesis of ischemia-re-
perfusion (IR) injury in the heart. The mechanisms involved, such as
induction of mitochondrial permeability transition or oxidative damage
of intramitochondrial structures and molecules, are modulated or ag-
gravated by mitochondrial ROS production, placing mitochondrial ROS
at the center stage of IR injury. The general view is that mitochondrial
oxidative stress is quite moderate during ischemia itself, but much more
pronounced during the burst of ROS at the onset of reperfusion as well
as during the hours and days following an ischemic insult. Moreover,
novel sources of mitochondrial ROS beyond that directly related to the
electron transport chain have been revealed, such as monoamine oxi-
dases, the p66Shc protein, and NADPH oxidase 4. The comprehensive
review by Heiko Bugger and Katharina Pfeil [13] provides an in-depth
report on the various sources of mitochondrial ROS as well as the
consequences of ROS, both in IR and post-infarction remodeling. The
authors also point to the challenge of finding an effective treatment
approach in human cardiac IR injury, which calls for additional studies
and testing of new compounds or treatment strategies.
Finally, Edoardo Bertero, Christoph Maack and coworkers [14]
discuss the essential role of cardiolipin in mitochondrial morphology,
metabolism, and respiration. Mitochondrial membranes are character-
ized by a unique lipid composition, and are the only cellular mem-
branes containing the phospholipid cardiolipin which play an essential
role in mitochondrial morphology, metabolism, and respiration. Mi-
tochondrial dysfunction has been implicated in the pathogenesis of
numerous disorders. In this review the authors discuss cardiolipin
biogenesis and function under physiological conditions and inherited
disorders characterized by perturbed cardiolipin biosynthesis and re-
modeling, namely Barth syndrome (BTHS), dilated cardiomyopathy
with ataxia (DCMA), and Sengers syndrome.
Taken together, the various reviews collected in this Special Issue of
Biochimica et Biophysica Acta – Molecular Mechanisms of Disease present
an updated understanding of the significance of metabolic homeostasis
in the cardiovascular system. Myocardial energy metabolism remains a
highly dynamic process that is pivotal for securing an optimal con-
tractile function. Detailed insight into the underlying molecular me-
chanisms is essential for identifying additional diagnostic and ther-
apeutic options to treat aberrations in cardiac functioning seen in the
failing heart.
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